Analysis of drug-induced effect patterns to link structure and side effects of medicines
暂无分享,去创建一个
[1] N. L. Johnson,et al. Multivariate Analysis , 1958, Nature.
[2] J. H. Ward. Hierarchical Grouping to Optimize an Objective Function , 1963 .
[3] L. W. Hamilton,et al. Sex differences in response to taste and postingestive consequences of sugar solutions , 1976, Physiology & Behavior.
[4] Turan M. Itil,et al. The discovery of antidepressant drugs by computer-analyzed human cerebral bio-electrical potentials (CEEG) , 1983, Progress in Neurobiology.
[5] Somatic symptoms in depression and antidepressants. , 1983, The Journal of clinical psychiatry.
[6] Allan R. Wilks,et al. The new S language: a programming environment for data analysis and graphics , 1988 .
[7] J N Weinstein,et al. Mining the National Cancer Institute Anticancer Drug Discovery Database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. , 1998, Molecular pharmacology.
[8] P. Labute,et al. Binary Quantitative Structure—Activity Relationship (QSAR) Analysis of Estrogen Receptor Ligands. , 1999 .
[9] I. Hindmarch. Myths, medicine and the media , 1999 .
[10] E. J. German,et al. Ocular effects of antimuscarinic compounds: is clinical effect determined by binding affinity for muscarinic receptors or melanin pigment? , 1999, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[11] S. Steiner,et al. Expression profiling in toxicology--potentials and limitations. , 2000, Toxicology letters.
[12] G. Rubanyi,et al. Identification of Selective Estrogen Receptor Modulators by Their Gene Expression Fingerprints* , 2000, The Journal of Biological Chemistry.
[13] B. Antkowiak. How do general anaesthetics work? , 2001, Naturwissenschaften.
[14] Lee Bennett,et al. Prediction of compound signature using high density gene expression profiling. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[15] J. Weinstein,et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data , 2002, The Pharmacogenomics Journal.
[16] Paul Labute,et al. A probabilistic approach to high throughput drug discovery. , 2002, Combinatorial chemistry & high throughput screening.
[17] E. Petricoin,et al. Clinical proteomics: translating benchside promise into bedside reality , 2002, Nature Reviews Drug Discovery.
[18] J. Rockett. Use of genomic data in risk assessment , 2002, Genome Biology.
[19] Ricard V. Solé,et al. A Model of Large-Scale proteome Evolution , 2002, Adv. Complex Syst..
[20] T. Zacharewski,et al. Workshop overview: use of genomic data in risk assessment. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.
[21] W. Dimpfel. Preclinical data base of pharmaco-specific rat EEG fingerprints (tele-stereo-EEG). , 2003, European journal of medical research.
[22] D. Goldstein,et al. Pharmacogenetics [7] (multiple letters) , 2003 .
[23] M. Tyers,et al. From genomics to proteomics , 2003, Nature.
[24] Dragos Horvath,et al. Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.
[25] M. Pellegrini. Defining interacting partners for drug discovery , 2003, Expert opinion on therapeutic targets.
[26] D. Sanger. The Pharmacology and Mechanisms of Action of New Generation, Non-Benzodiazepine Hypnotic Agents , 2004, CNS Drugs.
[27] Dan M. Bolser,et al. Comparative interactomics analysis of protein family interaction networks using PSIMAP (protein structural interactome map) , 2005, Bioinform..
[28] A. Fliri,et al. Biospectra analysis: model proteome characterizations for linking molecular structure and biological response. , 2005, Journal of medicinal chemistry.
[29] A. Fliri,et al. Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.